Status:
UNKNOWN
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
60-80 years
Phase:
PHASE4
Brief Summary
This study aims to evaluate the efficacy of dual therapy compared with bismuth-containing quadruple therapy as first-line treatment for Helicobacter Pylori eradication, as well as the safety and econo...
Eligibility Criteria
Inclusion
- having H. pylori related chronic gastritis confirmed by ¹³C-urea breath test, ¹⁴C-urea breath test and/or biopsy；
- underwent gastroscopy within 1 year before treatment, liver and renal function tests and electrocardiogram within 3 months before treatment；
- with no historical treatment for helicobacter pylori infection.
Exclusion
- administration of antibiotics, bismuth in 4 weeks prior to inclusion or antacids including H2 receptor antagonist, proton pump inhibitor and potassium-competitive acid blocker in 2 weeks prior to inclusion
- with previous esophageal or gastric surgery
- with severe systemic diseases, major organ like heart, lung, brain diseases, liver or kidney insufficiency, malignant tumor or other diseases
- allergy to any of the study drugs
- participated in other research within 3 months，cannot express his/her own ideas correctly or cannot cooperate with the researcher
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
393 Patients enrolled
Trial Details
Trial ID
NCT05419674
Start Date
August 1 2022
End Date
August 1 2023
Last Update
February 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China, 310009